Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4
1(33.3%)
Phase 3
1(33.3%)
N/A
1(33.3%)
3Total
Phase 4(1)
Phase 3(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03235687Not ApplicableUnknown

Decision Impact Trial of the ExoDx Prostate (IntelliScore)

Role: collaborator

NCT01136226Phase 4Completed

Evaluate Recovery of Testosterone for Patients Using Eligard

Role: lead

NCT00893113Phase 3Completed

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

Role: lead

All 3 trials loaded